Whalesbook
Famotidine Injection Approved by FDA
Lupin Ltd's recent announcement of US FDA approval for its famotidine injection USP, coupled with a significant boost in Q4 FY26 earnings, presents a mixed picture for investors. While the approval expands its injectable offerings, the product's modest market size contrasts sharply with the company's robust financial performance, prompting questions about market valuation and future growth expectations.
Famotidine Injection Gets FDA Green Light
The US Food and Drug Administration (FDA) has approved Lupin's famotidine injection USP, 20 mg/2 mL (10 mg/mL) single-dose vials. Manufactured at Lupin's Nagpur facility in India, this is bioequivalent to Merck Sharp & Dohme Corp's Pepcid Injection. It's indicated for hospitalised patients unable to take oral medication and for pathological hypersecretory conditions or intractable ulcers. The US market for this injection is estimated at $8.7 million annually, based on IQVIA MAT March 2026 data. This approval bolsters Lupin's portfolio of complex generics and injectables, a segment typically offering higher margins and better protection against price erosion than oral generics. However, the $8.7 million market size is relatively small compared to Lupin's total revenue, which exceeded ₹7,475 crore in Q4 FY26. Lupin's shares closed down 1.36% on May 13, 2026, suggesting the market may have anticipated this approval or views it as a minor addition rather than a major growth driver.
Strong Q4 Earnings Signal Financial Health
Lupin reported strong Q4 FY26 financial results, with consolidated net profit nearly doubling to ₹1,460 crore, fueled by its US generics business and widespread growth. Revenue climbed 31.9% year-over-year to ₹7,475 crore. For the full fiscal year 2026, net profit rose 62.5% to ₹5,333 crore on revenue growth of 23.1% to ₹27,958 crore. These figures surpassed some analyst expectations. Lupin's Nagpur facility, responsible for manufacturing injectables, maintains a strong compliance record with multiple US FDA inspections showing zero observations. The broader Indian generic injectables market is a key growth area, projected to expand significantly in the coming years. While the famotidine approval adds to Lupin's stake in this expanding sector, the company has also recently gained approval for products targeting much larger markets, including a generic HIV treatment with potential US sales exceeding $16 billion.
Why the Market Reaction is Muted
Several factors explain the muted market reaction, despite the positive news. The $8.7 million market for famotidine injection is a minor addition to Lupin's revenue, especially compared to recent approvals for products targeting much larger markets. Although the Nagpur facility has a clean FDA record, Lupin has faced regulatory issues at other sites, like the three USFDA observations at its Pithampur Unit-1 facility in September 2024. Management has also warned of potential US margin headwinds that could affect future profits. Analyst views are mixed, with some maintaining 'Buy' ratings and price targets around ₹2,580-₹2,600, while others have downgraded. Nuvama Institutional Equities moved the stock to 'Hold' from 'Buy', and Nomura kept a 'Buy' with a target of ₹2,580. Lupin's P/E ratio, ranging from 19x to 24x, suggests investors are already valuing the company based on significant future growth. Consequently, smaller approvals like famotidine may not significantly alter its valuation unless accompanied by broader strategic shifts or greater market penetration.
Analyst Views and Future Outlook
Lupin's future performance hinges on its success in launching and scaling more substantial pipeline products and improving margins across its markets. Analyst consensus generally supports a 'Moderate Buy' rating, with average 12-month price targets between ₹2,433 and ₹2,460. This suggests potential upside but also indicates that many institutions view the stock as trading near its fair value. Key growth drivers remain its pipeline of complex generics and injectables, supported by its established US and Indian market presence. Investors will be watching closely to see if Lupin can achieve sustained growth beyond its recent strong financial quarter.